Could a gut bacteria help treat lung cancer that stopped responding to immunotherapy?
NCT ID NCT06448572
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 35 times
Summary
This early-phase trial is testing whether a combination of a healthy gut bacteria (EXL01) and the immunotherapy drug nivolumab can help people with advanced non-small cell lung cancer that no longer responds to standard treatments. The study will enroll 21 adults whose cancer has progressed after prior immunotherapy and chemotherapy. Researchers will monitor how long the cancer stays under control and track any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU Lille
RECRUITINGLille, 59000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EXL01 (a single-strain gut bacteria called F. prausnitzii) combined with nivolumab
What this could lead to
If it works, this could point toward a new treatment option for advanced lung cancer patients who have run out of standard therapies.
What could go wrong
This is a very early, small pilot study with only 21 participants, so results may not apply broadly. The combination could also cause side effects or fail to improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.